At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 3 enrolled
Drug / intervention
Flortaucipir F18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A High Resolution Autopsy Study Evaluating the Relationship of 18F-AV-1451 PET Imaging and Tau Pathology
In Brief
A Phase 1 clinical trial evaluating Flortaucipir F18 for Alzheimer's Disease. Completed, enrolled 3 participants across 2 sites.
Detailed Summary
The study is designed to examine the relationship between imaging results detected on a 18F-AV-1451 PET scan and pathology found at autopsy within six months of imaging.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartNov 2016
Primary CompletionJun 2017
TodayJul 2026
First PostedJan 30, 2015
Enrollment StartNov 26, 2016
Primary CompletionJun 16, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.4 years ago
Interventions
Flortaucipir F18drug
Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq) (10 millicurie \[mCi\]) of flortaucipir.